CureVac COVID-19 vaccine

CureVac COVID-19 vaccine
INN: zorecimeran
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Other namesCVnCoV
CV07050101
Routes of
administration
Intramuscular
ATC code
  • None
Legal status
Legal status
  • EU: Terminated[1]
Identifiers
CAS Number
DrugBank
UNII

The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI).[3] The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.[4] In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.[5]

  1. ^ Zimmer C (12 October 2021). "CureVac has withdrawn its Covid vaccine application to European regulators". The New York Times. Retrieved 13 October 2021.
  2. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  3. ^ "CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". CureVac (Press release). 15 March 2020. Archived from the original on 8 March 2021. Retrieved 17 February 2021.
  4. ^ Burger L (16 June 2021). "CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy". Reuters. Retrieved 17 June 2021.
  5. ^ Szymanska Z, Burger L (12 October 2021). "CureVac drops COVID-19 vaccine, pins hope on next-generation shots". Reuters. Retrieved 30 December 2021.